Anal Cancer Survival Analysis
Research type
Research Study
Full title
Advanced survival analyses using routinely-collected hospital data in patients with anal cancer treated at the Christie NHS Foundation Trust (1988 to 2016)
IRAS ID
217577
Contact name
Hema Sekhar
Contact email
Sponsor organisation
The University of Manchester
Duration of Study in the UK
0 years, 11 months, 3 days
Research summary
Treatment of anal squamous cell carcinoma (ASCC) is primarily chemo-radiotherapy (CRT), with a high likelihood of local recurrence, when radical salvage surgery may be required. Data from trials over the past 25 years show that the use of CRT, and its refinement, is associated with improved locoregional control but without impact on overall survival. By contrast, population-level data in the UK suggests that overall survival may have improved over the past three decades, but such data lack detail on key factors like stage and treatment.
The central theme of this project is to use routinely collected hospital data (already held under clinical audit registration as a clinical database at The Christie NHS Foundation Trust, a regional specialist centre for the treatment of patients with anal cancer), to provide comprehensive analyses on oncological outcomes in patients with anal cancer in context of the variety of changes to its management over time. It will also provide accurate information on adverse indicators in anal cancer to help the development of risk-adapted therapy in future trials.
Within the framework of a University of Manchester registered PhD thesis, this protocol supports a HRA application to access pseudonymised clinical, pathological, treatment, and outcome variables from the Christie anal cancer clinical database (1988 to 2016).
There will be two steps in this project. First, extraction of data from an anal cancer database of a key number of required variables which will be delivered in a pseudonymised manner to the student researcher. Second, undertake a set of advanced statistical analyses (primarily survival analyses). Outcome measures will include, for example, overall survival, locoregional relapse, progression-free survival, and treatment-related adherence and morbidity.
The results will contribute to a PhD thesis, and associated publications.
REC name
West Midlands - Solihull Research Ethics Committee
REC reference
16/WM/0486
Date of REC Opinion
21 Nov 2016
REC opinion
Favourable Opinion